文献速递临床试验与 GCP

针刺治疗桥本甲状腺炎的随机对照试验研究方案

Acupuncture for Hashimoto thyroiditis: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2021-01-21

本研究为随机、盲法对照、评估者盲的预试验,计划招募60例桥本甲状腺炎患者,分为针刺组(手阳明经透刺,16周治疗+16周随访)和对照组(16周观察+16周补偿治疗)。主要结局为甲状腺抗体及甲状腺激素水平变化,次要结局包括生活质量和情绪量表,旨在评估针刺的可行性、疗效和安全性。

要点

  • 针刺组采用手阳明经透刺治疗16周,对照组先观察16周后交叉接受相同治疗。
  • 主要结局为TPOAb、TgAb及甲状腺激素(FT4、FT3、TSH)浓度变化。
  • 次要结局包括ThyPRO-39、SF-36和HAD量表,评估生活质量和情绪。

核心结论

  • 本试验旨在评估手阳明经透刺对桥本甲状腺炎患者降低甲状腺抗体水平和改善生活质量的可行性及有效性。

研究设计与样本

  • 随机、盲法对照、评估者盲的预试验,计划招募60例桥本甲状腺炎患者,实验组和对照组各30例。

关键数值与推荐

  • 实验组接受手阳明经透刺治疗16周,随后随访16周;对照组先观察16周,再接受16周补偿性透刺治疗。
  • 主要结局为抗甲状腺过氧化物酶抗体、抗甲状腺球蛋白抗体及甲状腺激素(总甲状腺素、游离甲状腺素、促甲状腺激素)浓度的变化。
  • 次要结局包括甲状腺相关生活质量问卷简表(ThyPRO-39)、MOS 36项短期健康调查(SF-36)和医院焦虑抑郁量表(HAD)。
  • 数据收集时间点:基线评估及第8、16、24、32周。

临床怎么用

  • 若试验证实有效,手阳明经透刺可能为桥本甲状腺炎伴甲状腺功能减退或亚临床甲状腺功能减退患者提供改善症状和生活质量的辅助治疗选项。

局限性

  • 本研究为预试验,样本量较小(60例),主要评估可行性和初步疗效,结果需进一步大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The incidence rate of Hashimoto thyroiditis (HT) has gradually increased in recent years. There has been no specific etiological treatment for HT. Even though with normal level of thyroid hormone, the patients may still suffer from various clinical symptoms, such as anterior neck discomfort, fatigue, and mood swings, which seriously impair their quality of life. Acupuncture has long been used in the treatment of thyroid diseases, but there has been no related standardized clinical study as of today. This study aims to assess the feasibility, efficacy, and safety of acupuncture for HT. METHODS: This is a randomized, black-controlled assessor-blinded pilot trial. A total of 60 patients will be recruited and divided into the experimental group (n = 30) or the control group (n = 30). The experimental group will undergo acupuncture therapy (penetration needling of Hand-Yangming meridian, PNHM) for 16 weeks, followed by a 16-week follow-up period, and the control group will first go through an observation period for 16 weeks, followed by a 16-week compensation PNHM therapy. The primary outcome will be the change of the concentrations of anti-thyroperoxidase antibodies (TPOAb), antithyroglobulin antibodies (TgAb), and thyroid hormone, including total thyroxine (FT4), free thyroxine (FT3), and thyroid-stimulating hormone (TSH). The secondary outcome measurements include the thyroid-related quality of life questionnaire short-form (ThyPRO-39), The Mos 36-item Short Form Health Survey (SF-36), and Hospital Anxiety and Depression Scale (HAD). Data collection will be performed before the start of the study (the baseline assessment) and at weeks 8, 16, 24, and 32. DISCUSSION: The study is designed to assess the feasibility and effectiveness of PNHM in reducing the thyroid antibody level and improving the quality of life of HT patients with hypothyroidism or subclinical hypothyroidism. Results of this trial will assist further analyses on whether the acupuncture treatment can alleviate symptoms for patients with HT. TRIAL REGISTRATION: Acupuncture-Moxibustion Clinical Trial Registry AMCTR-IOR-19000308 ( ChiCTR1900026830 ). Registered on 23 October 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wang S, Zhao J, Zeng W, et al. Acupuncture for Hashimoto thyroiditis: study protocol for a randomized controlled trial. Trials. 2021. PMID: 33478571. doi:10.1186/s13063-021-05036-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。